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Abstract 
Background: Diabetic retinopathy is one of most common and threatening ocular diseases. Many of these patients 
need to be submitted to panretinal photocoagulation (PRP), experiencing a significant level of pain. The purpose of 
this study is to evaluate the effectiveness of oral metamizole in reducing pain during PRP in patients with proliferative 
diabetic retinopathy (PDR) and very severe non-proliferative diabetic retinopathy (VSNDR).
Methods: Patients from a single center with PDR or VSNDR and indication of bilateral PRP were recruited for a dou-
ble-masked, controlled, prospective study. The treated eyes were randomly assigned in two groups, and each patient 
had one eye assigned per group. Group A received 1000 mg of metamizole and group B received a placebo pill 
40 min before the laser treatment. The groups were switched for the treatment of the fellow eye. Each patient scored 
the pain sensation immediately after each PRP section using Scott’s visual analogue scale (VAS). The paired Student 
t test was used to measure the significance between the two groups VAS scores, with significance level adopted of 
p < 0.05.
Results: Twenty-one patients were recruited. The level of pain was significantly lower when submitted to PRP 
after oral metamizole treatment compared to placebo (p = 0.002). The mean pain scores for groups A and B were 
4.72 ± 1.708 and 5.89 ± 1.967, respectively. The minimum/maximum scores within groups A and B were 1/8 and 
1/10, respectively.
Conclusions: The use of 1000 mg of metamizole 40 min before PRP significantly reduces the pain associated with 
the procedure in patients with PDR or VSNDR.
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Background
Diabetic retinopathy is one of the most important causes 
of visual impairment in adult population. The stand-
ard treatment in the last few decades for eyes with high 
risk of visual loss, with very severe nonproliferative dia-
betic retinopathy (VSNDR) or proliferative diabetic 
retinopathy (PDR), has been the administration of laser 
panretinal photocoagulation (PRP) [1–4]. The Diabetic 
Retinopathy Study and, subsequently, the Early Treat-
ment Diabetic Retinopathy Study demonstrated the effi-
cacy of photocoagulation treatment for these situations 
[5].
Most of the patients undergoing PRP treatment com-
plain about moderate to severe pain sensation. Previous 
studies show that 73 % of the patients submitted to PRP 
report painful sensation during the laser treatment [6–8]. 
Different strategies have been tried to relieve the level 
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of pain associated with the procedure, such as peribul-
bar anesthesia [6, 9, 10], oral [11] and topical diclofenac 
[12], oral diazepam, oral mephenamic acid, oral aceta-
minophen or intramuscular ketorolac tromethamine [6], 
but there is no solid consensus or good evidence of the 
efficacy for any of them [13].
Metamizole, also known as dipyrone, is widely used as 
an analgesic in many countries (Switzerland, Germany, 
France, Spain, Latin and South America, Far East and 
Africa) [14]. Although its mechanism of action is not well 
known, inhibition of cyclooxygenase has been demon-
strated, with a peak of action 40 min after the administra-
tion [14–16]. Despite the controversial increased risk of 
metamizole-associated hematological adverse reactions, 
several studies have used this drug as a comparative anal-
gesic in post-operative analgesy [17–21], and eye surgery 
trials [22], with well documented safety characteristics by 
several papers [14, 23–25].
The purpose of our study is to analyze if metamizole, 
a common oral analgesic widely used in South America, 
is effective in reducing painful sensation during retinal 
laser treatment in patients with PDR or VSNDR [6, 11].
Methods
We performed a randomized, double-masked clinical 
trial to evaluate the efficacy of metamizole as a pre-emp-
tive analgesic agent during PRP. Patients with bilateral 
PDR or VSNRD from the Ophthalmology Service of the 
Hospital das Clínicas—University of São Paulo Medi-
cal School that were recruited over a 2-year period were 
included. All patients signed an informed consent form 
and the ethics committee approval was obtained before 
the beginning of the study.
Inclusion criteria were: bilateral proliferative diabetic 
retinopathy or very severe non-proliferative diabetic 
retinopathy, no previous laser treatment, best corrected 
visual acuity of 20/200 or better, intraocular pressure 
under 21  mmHg, spherical equivalent of ±5.00 diop-
ters, clear media and vitreous, diabetes diagnosed after 
30  years of age. The exclusion criteria were: previous 
photocoagulation treatment, media opacity such as cata-
racts, corneal diseases or vitreous hemorrhage, unilateral 
PDR, chronic use of analgesics or history of any side-
effects related to metamizole use.
All patients were submitted to PRP, divided in two ses-
sions per eye. PRP was performed by two specific authors 
(RBA and BMSA) who were blind to the pre-emptive 
treatment in all sessions. A third professional (BSG) was 
responsible for administering the drug or the placebo to 
the patient. The eyes of each patient were randomized 
into groups A and B. Randomization tables were sent to 
the pharmacist who allocated each pill in a randomized 
sequence. Group A eyes received 1000 mg of metamizole 
40  min before the laser session and group B eyes were 
medicated with a placebo pill. Each patient had one eye 
on group A and one eye on group B. Therefore, a group 
of patients took metamizole before any PRP, and had PRP 
with placebo at the fellow eye, while a group of patients 
started PRP with placebo pills, and had PRP with meta-
mizole when treating the second eye.
Before the laser treatment sessions, each patient was sub-
mitted to a complete ophthalmological examination, that 
consisted of best-corrected visual acuity (BCVA) measure-
ment, biomicroscopy, gonioscopy, tonometry and fundos-
copy. Each patient had his or her pupils dilated with topical 
1 % tropicamide. The laser treatment was performed with 
green argon double-frequency laser with a panretinal con-
tact lens. Each session consisted in approximately 500 spots, 
with laser energy adjusted to achieve moderate white burns, 
spots size of 250 micrometers and exposure time of 0.2  s. 
The inferior and nasal retina was treated in the first session, 
and superior and temporal retina in the second session.
The painful sensation scores were evaluated immedi-
ately after finishing each session with the Scott’s Visual 
Analogue Scale (VAS), that ranges from 0 (no pain at all) 
to 10 (the worst pain imaginable).
Statistical analysis was expressed in mean, maximum, 
minimum scores obtained, and standard deviation. Sam-
ple size was calculated considering a pain score differ-
ence of 2 points between both groups, with Alfa error of 
5 % and beta error of 20 %. All data was processed with 
SPSS version 20.0. The paired Student t test was used to 
measure the significance between the two groups, with 
significance level adopted of p < 0.05.
Results
A total of 21 patients (42 eyes) were recruited and their 
characteristics are summarized in Table  1. The eyes of 
each patient were randomized to groups A and B. There 
was no statistically significant difference in gender, age, 
race and diagnosis (type I or II diabetes) between groups. 
The mean age of the patients was 52.90  ±  9.42  years, 
ranging from 31 to 66 years.
All patients took their appropriate pretreatment 
medications (metamizole or placebo, for groups A or 
B respectively), underwent their first PRP session, and 
answered the pain questionnaire. At the very next visit 
(1 week later), patients were submitted to the same PRP 
procedure at the fellow eye and therefore took a differ-
ent pill (Placebo for those that had taken metamizole; 
metamizole for the patients that had taken placebo).
Laser parameters delivered to the patients were simi-
lar between the groups and there was no statistical dif-
ference between groups regarding the number of spots 
delivered, as shown in Table  2. Pain score differences 
based on the retinal area treated.
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The mean VAS pain scores for groups A and B were 
4.72 ± 1.71 and 5.89 ± 1.97 (p < 0.01), respectively. The 
minimum/maximum scores within groups A and B were 
1/8 and 1/10, respectively (Table  3). There were no sig-
nificant differences in the pain scores between the groups 
regarding gender, race, age or educational level, or to 
laser intensity parameters. The laser parameters values 
are shown in Table 4.
Patients referred a significant lower level of pain dur-
ing PRP when submitted to previous oral metamizole 
treatment when compared to placebo (p  =  0.002). No 
serious adverse events or drug allergy related to metami-
zole were reported.
Discussion
Most patients undergoing PRP typically experience pain 
during the procedure, which may be so uncomfortable that 
there is a risk of inadequate treatment being applied or 
perhaps the patient may even default from attendance [7].
There are numerous options available to reduce or pre-
vent it. Retrobulbar, peribulbar, or subtenon anesthesia 
are effective pain-relieving procedures, but are invasive 
for patients and possess risk of potential complications 
and therefore are not feasible for in-office daily routine 
[16, 26]. On the other hand, previous results [6] suggest 
that oral diazepam, acetaminophen, mefenamic acid, 
and intramuscular injection of ketorolac tromethamine 
are not effective to reduce pain severity associated with 
PRP. One study found reasonable results in reducing pain 
scores with oral etoricoxib [27].
This study sought to find an inexpensive, safe and easy-
to-administer method to reduce the pain intensity felt 
during PRP. It would make the treatment more comfort-
able for patients, would likely decrease the need for res-
cue injection anesthesia, and could potentially improve 
compliance with follow-up PRP treatments [11].
Metamizole is a non-opioid analgesic and one of the 
most frequently used analgesics around the world, there-
fore it was chosen for this study to evaluate its analgesic 
effects. However, in some countries, the drug has been 
avoided since the 1970s because of what was thought to 
be an unacceptable risk of agranulocytosis. Recent scien-
tific data do not justify this reasoning [16].
Its mechanism of action is still under discussion, but 
the main pathway is attributed to an inhibition of prosta-
glandin synthesis in both peripheral tissues and the cen-
tral nervous system [17].
The results of this study show a positive effect of meta-
mizole in reducing pain caused by PRP. It is known that 
pain perception is a personal experience to each individ-
ual. Many factors can influence this perception, including 
gender, cultural differences, past experiences, and anxiety 
levels [17].
Table 1 Demographic data from both treated groups
Group characteristics
Age
 Mean value (years) 52.9 (±9.4)
N %
Sex
 Female 10 47.6
 Male 11 52.4
Education
 Preliminary school 11 52.4
 High school 8 38.1
 None 2 9.5
Race
 White 12 57.1
 Black 4 19.0
 Miscegenous 5 23.8
Diabetes
 DM type 1 4 19.0
 DM type 2 17 81.0
Total 21 100.0
Table 2 Laser treatment specifications of  both group A 
and B: number of spots per session
There was no statistical difference between both groups A and B concerning the 
average number of laser spots per session
Number of  
spots
Minimum Maximum Mean SD
Group A 424 603 509.33 42.89
Group B 266 576 496.90 58.85
Table 3 Visual analogue scale pain scores, with  mean and  standard deviation (SD), maximum and  minimum values 
for each group
The mean pain score value was higher in the placebo group, in comparison with the metamizole group. Statistical significance is showed on the table. Note that only 
in the placebo group the maximum pain score was achieved
Treatment groups Metamizole Placebo ρ value
Mean ± SD (Minimum–maximum) Mean ± SD (Minimum–maximum)
VAS (visual analogue scale) 4.72 ± 1.71 (1–8) 5.89 ± 1.97 (1–10) 0.002
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In order to avoid any kind of bias, we selected bilateral 
cases that had never experienced laser before. Moreo-
ver, the same patient was submitted to PRP after either 
placebo or metamizole (only the order of it was rand-
omized). Our intention was to create the best scenario in 
order to make unbiased comparison.
The main limitations of our study are the lack of assess-
ment of differences regarding the pain report between 
first and second laser session or between different reti-
nal areas, which should be aim of further studies. Despite 
the significant results, this is a small trial and our results 
should be confirmed by other future studies.
Furthermore, an important observation in this study was 
the similar laser parameters applied to bot. The occurrence 
of pain in PRP may be influenced by many parameters, such 
as duration, intensity, spot size and obviously the number 
of spots delivered in each session. Recent literature evalu-
ates the pain response with reduced exposure laser times 
and micropulse technology, with good pain score outcomes 
[12, 18, 19]. The parameters used during our study were 
carefully selected before its start. However, patients experi-
encing severe pain during PRP may ask to stop treatment. 
Fortunately, our analysis showed that there was no differ-
ence in number of spots delivered among groups; there-
fore we believe this kind of bias did not interfere with our 
outcomes.
Conclusion
In conclusion, PRP is a painful treatment for most 
patients. According to our study, the use of 1000 mg of 
metamizole 40  min before PRP significantly reduces 
the pain associated with the procedure in patients with 
proliferative diabetic retinopathy or VSNDR. Therefore, 
metamizole is a safe and cheap option that can be applied 
before the procedure, especially in patients with no his-
tory of drug allergy, resulting in more comfort to patients 
with PDR or VSNDR.
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